Formulation and evaluation of mucoadhesive microspheres of tenofovir disoproxil fumarate for intravaginal use

Current Drug Delivery

Volumn 11, Issue 1, 2014, Pages 112-122

  Khan, Arshad Bashir ^a   Thakur, Ram Sharnagat ^a  

^a KRUPANIDHI COLLEGE OF PHARMACY   (India)

Author keywords

Chitosan; HIV; Microbicide; Microspheres; Tenofovir disoproxil fumarate

Indexed keywords

CHITOSAN; MICROSPHERE; POLYMER; TENOFOVIR DISOPROXIL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CURVE FITTING; DRUG FORMULATION; DRUG STABILITY; ENCAPSULATION; EX VIVO STUDY; FEMALE; FOURIER TRANSFORM INFRARED PHOTOACOUSTIC SPECTROSCOPY; GELATION; IN VITRO STUDY; MICROSCOPY; MUCOADHESION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; X RAY DIFFRACTION;

ADENINE; ADHESIVENESS; ADMINISTRATION, INTRAVAGINAL; ANTI-HIV AGENTS; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; CROSS-LINKING REAGENTS; DRUG CARRIERS; FEMALE; HUMANS; KINETICS; MICROSPHERES; MODELS, CHEMICAL; MUCINS; PARTICLE SIZE; PHOSPHOROUS ACIDS; POLYPHOSPHATES; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 84894026315     PISSN: 15672018     EISSN: 18755704     Source Type: Journal    
DOI: 10.2174/156720181000131028120709     Document Type: Article

References (12)

1. Global Report: UNAIDS report on Global Aids pandemic. Joint United Nations Programme on HIV/AIDS (UNAIDS); 2012.
2. Global Report: UNAIDS report on Global Aids pandemic. Joint United Nations Programme on HIV/AIDS (UNAIDS); 2010.
3. US FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations [Internet].USA. Office of Generic drugs, Division of labeling and Program support; 2001 Oct 26 [updated 2013 July 25]. Available from: http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm?Appl_No=021356&TABLE1=OB_Rx.
4. De-Clercq, E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int. J. Antimicrob. Agents, 2009, 33, 307-320.
5. Mesquita, P.M.M.; Rastogi, R.; Segarra, T.J.; Teller, R.S.; Torres, N.M.; Huber, A.M. Intravaginal ring delivery of tenofovirdisoproxilfumarate for prevention of HIV and herpes simplex virus infection. J. Antimicrob. Chemother, 2012, 67, 1730-38.
6. Aranaz, I., Mengíbar, M., Harris, R., Paños, I., Miralles, B., Acosta, N., Galed, G, Heras, A. Functional Characterization of Chitin and Chitosan. Curr. Chem. Biol., 2009, 3, 203-230.
7. Khan T.A.; Peh K.K.; Chng, H.S. Mechanical, bioadhesive strength and biological evaluations of chitosan films for wound dressing. J. Pharm. Pharm. Sci., 2000, 3(3), 303-11.
8. He, P., Davis, S.S., Illum, L. In vitro evaluation of the mucoadhesive properties of chitosan Microspheres. Int. J. Pharm., 1998, 166, 75-68.
9. Patel, M.P.; Patel, R.R.; Patel, J.K. Chitosan Mediated Targeted Drug Delivery System: A Review. J. Pharm. Pharm. Sci., 2010, 13(3) 536-557.
10. Nakamura, F.; Ohta, R.; Machida, Y.; Nagai, T. In vitro and in vivo nasal mucoadhesion of water soluble polymers. Int. J. Pharm., 1996, 134, 173-181.
11. Govindan, S.; Nivethaa, E.A.K.; Saravanan, R.; Narayanan, V., Stephen, A. Synthesis and characterization of chitosan-silver nanocomposite. App. Nanosci., 2012, 10.1007/s13204-012-0109-5.
12. Anker, J.; Dova, E.; Mazurek, J.M. Ultimorphix technologies BV assignee. TenofovirDisoproxil Hemi-Fumaric Acid Co-Crystal. United States patent US20090270352 A1.2009 Oct 29.